INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement

Nov 28, 2023 | Press Releases

SARASOTA, Fla., Nov. 28, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a healthcare services company focused on expanding access to advanced fertility treatment worldwide with its INVOcell® medical device and...

INVO Reports Record Third Quarter 2023 Financial Results

Nov 13, 2023 | Press Releases

Company Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Conditions Pertaining to the Announced Merger Agreement with NAYA Biosciences SARASOTA, Fla., Nov. 13, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO)...

NAYA Biosciences and INVO Bioscience Announce Appointment of Dr. Peter Kash, Ed.D., MBA as Vice Chairman Following Closing of Their Pending Merger

Nov 10, 2023 | Press Releases

SARASOTA, Fla. and AVENTURA, Fla., Nov. 10, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO”), a healthcare services company focused on expanding access to advanced fertility treatment worldwide, and NAYA Biosciences Inc. (“NAYA”), a...

INVO Bioscience Announces Commencement of Waiver Solicitation From Holders of the Company’s Common Stock Purchase Warrants

Nov 9, 2023 | Press Releases

SARASOTA, Fla., Nov. 9, 2023 — INVO Bioscience, Inc. (Nasdaq: INVO) (“INVO” or the “Company”), a healthcare services company focused on expanding access to advanced fertility treatment worldwide with its INVOcell® medical device and...

Free Registration Is Now Open For Tribe Public’s CEO and Q&A Presentation Webinar Event “Accelerating Biotech Value Creation” Featuring NAYA Biosciences CEO Dr. Daniel Teper On Tuesday, October 31, 2023

Oct 27, 2023 | Press Releases

An Introduction to NAYA Biosciences with CEO Dr. Daniel TeperManaging unprecedented medical innovation in an era of financial market volatilityIncreasing patient access to breakthrough treatments in oncology, regenerative medicine, and fertilitySARASOTA, Fla. and...